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Abstract
Background: The clinical diagnosis of pertussis is not easy in early infancy since clinical manifestations can overlap
with several different diseases. Many cases are often misclassified and underdiagnosed. We conducted a
retrospective study on infants to assess how often physicians suspected pertussis and the actual frequency of
Bordetella pertussis infections.
Methods: We analyzed all infants with age ≤90 days hospitalized from March 2011 until September 2013 for acute
respiratory symptoms tested with a Real Time Polymerase Chain Reaction able to detect Bordetella pertussis and
with a Real Time Polymerase Chain Reaction for a multipanel respiratory virus. Therefore, we compared patients
with pertussis positive aspirate, patients with respiratory virus positive aspirate and patients with negative aspirate
to identify symptoms or clinical findings predictive of pertussis.
Results: Out of 215 patients analyzed, 53 were positive for pertussis (24.7 %), 119 were positive for respiratory virus
(55.3 %) and 43 had a negative aspirate (20 %). Pertussis was suspected in 22 patients at admission and 16 of them
were confirmed by laboratory tests, while 37 infants with different admission diagnosis resulted positive for
pertussis. The sensitivity of clinical diagnosis was 30.2 % and the specificity 96.3 %. Infants with pertussis had more
often paroxysmal cough, absence of fever and a higher absolute lymphocyte count than infants without pertussis.
Conclusions: Pertussis is a serious disease in infants and it is often unrecognized; some features should help
pediatricians to suspect pertussis, but clinical suspicion has a low sensitivity. We suggest a systematic use of Real
Time Polymerase Chain Reaction to support the clinical suspicion of pertussis in patients with less than 3 months of
age hospitalized with acute respiratory symptoms.
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Background
Despite a widespread vaccination program, pertussis
continues to be a common worldwide infection in
pediatric and adult populations. In the past decade, there
has been a resurgence of this disease in United States
and European countries, peaking every 2 to 5 years [1–
7]. The last peak reported in Europe was in 2012 [8].
In contrast to what is reported in other countries, in
Italy after the introduction of acellular vaccine in 1995
incidence has continued to decrease and pertussis has
not reemerged yet [9, 10]. Therefore epidemic cycles
have been clearly less identifiable due to the low inci-
dence [10]. In our country, vaccination schedule pro-
vides a pertussis vaccine dose at 3, 5 and 12 months and
a booster is recommended in the preschool period and
in adolescents. Vaccination coverage during the analyzed
period was around 95 % [11].
Since other countries with high immunization cover-
age over a long period of time experienced a resurgence
of pertussis [3, 5], we hypothesized that the epidemi-
ology of this disease in Italy may be affected by the lack
of recognition by clinicians with the consequence of lim-
iting the use of laboratory confirmation [9]. In clinical
practice the diagnosis of pertussis is generally reached
without microbiological confirmation leading to a* Correspondence: annachiara.vittucci@opbg.net1General Pediatric and Infectious Diseases Unit, Bambino Gesù Children’s
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possible lack of clinical awareness to start early treat-
ment and prevent complications.
Infants are known to acquire pertussis from adolescents’
and adults’ contacts that return susceptible to the disease
because of waning immunity as well as from unvaccinated
children [12–14]. Clinical manifestations may be different
depending on age. Severe symptoms are common in
young unvaccinated infants and pertussis continues to be
a major cause of vaccine-preventable death in this age
group [15]. However, cases with atypical clinical presenta-
tions do occur and may be often unrecognized, especially
during the winter season, when other respiratory viruses
circulate and the minimum incidence of pertussis is usu-
ally observed. The annual seasonality in the Italian pertus-
sis incidence peaked between March and August while
the minimum incidence has been observed between
September and February [10].
We therefore systematically studied a series of infants
≤3 months of age hospitalized with respiratory symp-
toms to detect how frequently physicians suspected per-
tussis on a clinical basis and the actual frequency of
laboratory confirmed cases. We compared patients with
pertussis infections and patients with other respiratory
infections to identify clinical and laboratory predictors
of pertussis.
Methods
The study involved patients with age ≤3 months admit-
ted at Pediatric Department of Bambino Gesù Children’s
Hospital in Rome from March 1st, 2011 until September
30th, 2013, with acute respiratory symptoms or condi-
tions (cough, dyspnea, rhinorrhea, bronchiolitis, apnea,
acute life threatening episode). For all the patients, a
nasopharyngeal specimen was tested for Bordetella per-
tussis (BP) and for viruses generally associated to re-
spiratory infections (RV) such as Adenovirus, Influenzae
Virus, Parainfluenzae Virus, Respiratory Syncytial Virus
(RSV), Metapneumovirus, Coronavirus and Rhinovirus.
The samples were obtained within 24 h of admission by
trained nurses and processed within 48–72 h.
The medical records of subjects were retrospectively
reviewed. Information collected included age, gender,
medical history, immunization status, clinical presenta-
tion, ongoing antibiotic therapy, admission diagnosis,
length of illness, length of hospital stay, laboratory test
results, concurrent infections and complications (re-
quirement of oxygen therapy, pneumonia, death).
Patients who had received the first dose of DPT vac-
cine were excluded from the study.
For nucleic acid extraction 10 μl of internal control
(IC) were added to 200 μl of sample for BP and to
400 μl for RV, obtaining 90 and 60 μl of eluate respect-
ively, by using the automatic “magnetic beads-based”
EZ1 Advanced XL (Qiagen) instrument.
Primers and Probe for IC were provided by the manu-
facturer (Argene, Biomerieux, Marcy l’Etoile, France).
The IC in use for this assay is referring to a “capsided”
synthetic sequence that need to be lysed before being
processed in extraction protocol and handled as well as
“regular” specimen.
The bacterial DNA was processed immediately on
Taqman platform (Applied Biosystem) with Bordetella
R-gene™ assay (Argene, Biomerieux, Marcy l’Etoile,
France), able to amplify a fragment of 191 bp of the tar-
get region IS481 for BP. The ready-to-use amplification
mixture included primers, dNTPs, amplification buffer,
Taq Polymerase, probes specific for Bordetella and for
the IC. The target DNA was amplified through the Taq
Polymerase activation at 95 °C for 15 min, and 45 re-
peats of denaturation at 95 °C for 10 s and
hybridization/elongation at 60 °C for 40 s.
The Real Time-Polymerase Chain Reaction (RT-PCR)
targeting IS481 is the most commonly used diagnostic
tool when suspecting pertussis given its high sensitivity
since up to 238 copies of IS481 is found in the BP gen-
ome. The high sensitivity does not correspond to high
specificity, as few copies of IS481 are also present in the
genome of Bordetella holmesii and Bordetella bronchi-
septica [16].
We assumed as positive patient for pertussis a subject
who received a positive RT-PCR result (following de-
scribed as BP+).
For RV detection samples were analyzed by reverse
transcription and gene amplification with RT-PCR.
All procedures performed in studies were in accordance
with the ethical standards of the institutional and national
research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
The study was approved by the Institutional Scientific
Review Board of Bambino Gesù Children’s Hospital.
Statistical analysis
We described the characteristics of patients, their
symptoms and clinical findings. Patients were divided
into three groups: patients with BP positive aspirate
(BP+), patients with RV positive aspirate (RV+) and
patients with BP and RV negative aspirate (BP-RV-).
Comparisons across groups were performed through
ANOVA for continuous measures and chi-square for
discrete variables. To assess the symptoms or clinical
findings predictive of pertussis we applied a logistic
regression model in which the dependent variable was
dichotomous (pertussis yes/no).
We also calculated the specificity and sensitivity of
clinical suspicion of pertussis using as gold standard the
result of RT PCR for pertussis on nasopharyngeal
aspirate.
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Results
During the study period, we enrolled 215 patients. The
admission diagnosis of those patients is reported in
Table 1.
Out of 215 patients tested, 53 had a positive RT-PCR
for BP (24.7 %). Of the 162 patients resulted negative for
BP, 119 were positive for RV infections (55.3 %): RSV
was diagnosed in 48 (40.3 %), Rhinovirus in 37 (31.1 %),
Parainfluenzae Virus in 9 (7.6 %), Adenovirus in 4
(3.4 %), Metapneumovirus in 4 (3.4 %), Influenzae Virus
in 3 (2.5 %), Coronavirus in 3 (2.5 %), Rhinovirus +
Adenovirus in 4 (3.4 %), Rhinovirus + Coronavirus in 2
(1.7 %), RSV + Adenovirus in 2 (1.7 %), Parainfluenzae
virus +Metapmeumovirus in 2 (1.7 %), RSV + Corona-
virus in 1 (0.8 %).
No etiological agent was identified on nasopharyngeal
aspirate of 43 patients (20 %). Those patients were dis-
charged with the following diagnoses: apnea (ICD-9 code
78609) (21), bronchiolitis (13), laryngitis/laryngomalacia
(3), unexplained fever in infants (2), sepsis (1), pneumo-
nia (1), intraventricular septal defect (1), HHV6 enceph-
alitis (1).
At admission, pertussis was clinical suspected in 22
patients only on the basis of the WHO definition. Six-
teen of them had a positive RT-PCR for BP, while the 6
patients resulted negative to BP were discharged with
diagnosis of bronchiolitis in 5 cases (2 RSV, 2 Rhinovirus
and 1 Parainfluenzae Virus) and apnea in 1 case (nega-
tive nasopharyngeal aspirate). On the other hand, among
the remaining 193 patients who had a different diagnosis
at admission, 37 were RT-PCR positive for BP. Thus the
sensitivity of clinical diagnosis at admission was 30.2 %
(19.52–43.54) and the specificity 96.3 % (92.16–98.29).
The clinical and laboratory characteristics on admis-
sion were compared between BP+ patients, RV+ patients
and BP-RV- patients (Table 2). Cough, paroxysmal
cough, whoop, apnea, fever, rhinorrhea, white blood
count, lymphocytes count, length of symptoms before
admission and length of hospital stay were statistically
different among the three groups.
When we applied the logistic regression model to
explore predictive clinical manifestations and/or la-
boratory test for pertussis, data showed that paroxys-
mal cough, absence of fever, absolute lymphocyte
count >10.000 n/mm3 and duration of symptoms before
admission ≥5 days were significantly associated with per-
tussis compared with other diagnoses (Table 3).
Notably, when we analyzed the length of symptoms
before admission of patients with BP+ we found that 20
patients (37.7 %) reported symptoms for less than 7 days;
20 patients (37.7 %) reported symptoms for 7- < 14 days
and 13 of them (24.5 %) reported symptoms for more
than 14 days.
Therefore, our data showed that apnea is not predict-
ive for pertussis, but it’s a frequent clinical manifestation
(30/53); among BP+ patients, 22 (41.5 %) reported apnea
associated with cough and cyanosis, while 8 of them
(15.1 %) reported apnea alone not associated with other
symptoms.
Complications (oxygen requirement and pneumonia)
were not statistically different in the three groups. No
deaths were reported (Table 2).
Regarding ongoing antibiotic therapy, 34 of our pa-
tients (9 BP+, 21 VR+, 4 BP-/VR-) had already started
antibiotics before admission; particularly, 19 patients
(7 BP+, 10 VR+, 2 BP-/VR-) had already started
macrolide therapy when specimens were collected.
When we analyzed the seasonal trend of our BP+ pa-
tients, we found that the maximum incidence was be-
tween June and September, but we had cases even in
winter with a peak in February (Fig. 1).
With regard to coinfection, of the 53 pertussis cases,
18 (34 %) had a positive RV result in addition to BP: 8
patients had PCR positive for Rhinovirus, 4 for Corona-
virus, 1 for RSV, 1 for Metapneumovirus, 1 for Parainflu-
enza Virus, 1 for Influenza + Coronavirus, 2 for
Rhinovirus + Parainfluenza. We didn’t find any signifi-
cant differences between patients with pertussis as
monoinfection and patients with pertussis plus RV
infection.
Discussion
The clinical suspicion of pertussis is not easy in infants.
Among the 53 patients BP+, pertussis was suspected
only in 16 patients (30.2 %) at the admission. Clinical
suspicion has a low sensitivity in this age group. In ab-
sence of a systematic use of laboratory tests for the diag-
nosis of pertussis in infants with respiratory symptoms,
many infants with BP infection may go unrecognized
[17]. In a hospital environment, the lack of recognition
of such an infection may represent a severe risk for hos-
pital outbreaks, since pertussis may be transmitted to
contacts if appropriate antibiotic therapy is not applied.
Table 1 Diagnosis at admission of the 215 patients tested for
Bordetella pertussis
Diagnosis at admission Patients (n = 215) BP+ (n = 53) Percent
Bronchiolitis 101 20 19.8
Apnea 41 8 19.5
Fever in infants 23 1 4.3
Suspected pertussis 22 16 72.7
Cough 19 8 42.1
Pneumonia 4 0 0
ALTE 5 0 0
BP+ patients with Bordetella pertussis positive aspirate, ALTE acute life
threatening episode
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As a matter of fact we did not observe any hospital sec-
ondary pertussis case over the study period.
Our data suggest that, despite routine surveillance
shows a low incidence of pertussis in Italy, BP infec-
tion is still circulating in unvaccinated infants and
nearly 25 % of patients younger than 3 months of age
hospitalized with respiratory symptoms resulted posi-
tive for BP in our case series, according to what pre-
viously reported [18]. Clinical manifestations of
pertussis can overlap with those of other diseases and
can be atypical. Nonetheless our data, in line with the
literature [19–21], suggest that some feature should
alert clinicians to suspect pertussis: the hallmark clin-
ical characteristic is paroxysmal cough; fever is usu-
ally absent and laboratory findings showed marked
lymphocytosis. On the other hand the absence of typ-
ical symptoms does not exclude the diagnosis of
pertussis.
Furthermore, it has been demonstrated that vaccinated
children and adolescents could have more silent or mild
pertussis infections [22, 23]; so we might expect that in-
fants born to mothers who had received Tdap during
pregnancy could present a modified pertussis. In our
series, no infants were born to mothers who had re-
ceived a booster during pregnancy.
Table 2 Demographic, clinical and laboratory characteristics of study patients
BP+ VR+ BP-/VR- p
(n = 53) (n = 119) (n = 43)
Age (days)a 56.20 ± 21.66 51.62 ± 20.59 50.16 ± 22.96 0,3
Male gender 34 (64.2 %) 66 (55.5 %) 24 (55.8 %) 0.56
Cough 45 (84.9 %) 100 (84 %) 18 (41.9 %) <0.001
Paroxysmal cough 16 (30.2 %) 7 (5.9 %) 1 (2.3 %) <0.001
Apnea 30 (56.6 %) 26 (21.8 %) 23 (53.5 %) <0.001
Emesis 10 (18.9 %) 25 (21 %) 5 (11.6 %) 0.39
Whoop 4 (7.5 %) 0 2 (4.7 %) 0.015
Fever 1 (1.9 %) 39 (32.8 %) 8 (18.6 %) <0.001
Rhinorrhea 0 24 (20.2 %) 3 (7 %) 0.001
Dyspnea 4 (7.5 %) 19 (16 %) 10 (23.3 %) 0.1
WBC (n/mm3)a 17.432 ± 9.332 11.908 ± 5.586 11.300 ± 3.731 <0.001
L (n/mm3)a 10.553 ± 6.349 5.278 ± 2.996 5.728 ± 2.442 <0.001
CRP (mg/dl)a 0.19 ± 0.43 0.76 ± 1.4 0.6 ± 1.1 0.046
Length of symptoms before admission (days)a 9.07 ± 6.68 3.13 ± 2.87 3.72 ± 4.03 <0.001
Length of hospital stay (days)a 8.06 ± 4.56 6.19 ± 3.00 8.76 ± 7.99 0.001
Complications
O2therapy 13 (24.5 %) 33 (27.7 %) 9 (20.9 %) 0.66
Pneumonia 3 18 3 0.12
Death 0 0 0 -
BP+ patients with Bordetella pertussis positive aspirate, RV+: patients with respiratory virus positive aspirate, BP-RV- patients with Bordetella pertussis and
respiratory virus negative aspirate, WBC white blood count, L lymphocyte count, CRP C-reactive protein
aexpressed as mean ± SD
Table 3 Association of clinical variables with laboratory
confirmed pertussis
aOR 95 % CI p
Age 0.995 0.972;1.019 0.68
Male gender 0.406 0.133;1.238 0.11
Cough 1.607 0.413;6.254 0.49
Paroxysmal Cough 7.535 1.495;37.985 0.01
Apnea 1.095 0.285;4.209 0.89
Emesis 0.616 0.128;2.959 0.54
Whoop 3.303 0.363;30.048 0.28
Absence of Fever 15.130 1.337;171.194 0.02
Rhinorrhea undefined undefined -
Dyspnea 0.902 0.169;4.827 0.90
WBC >18.000 n/mm3 1.289 0.196;8.487 0.79
L >10.000 n/mm3 21.922 3.368;142.693 0.001
CRP <0.5 mg/dl 0.598 0.149;2.402 0.46
Length of symptoms before
admission >5 days
3.782 1.316;10.870 0.01
WBC white blood count, L lymphocyte count, CRP C-reactive protein
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Of note, eight of our patients (15.1 %) with confirmed
BP infection were admitted with diagnosis of apnea, not
associated with other symptoms, according to what pre-
viously reported by Crowcroft and Shojaei [24, 25]. In
the ECDC pertussis case definition of 2012, apnoeic epi-
sodes in infants are included in the clinical criteria [26].
The lack of recognition of BP infection in infants has
important consequences for surveillance. The number of
infections that our hospital detected in the study period
does not seem consistent with national surveillance data
that suggest a low circulation of pertussis in the first
year of life. Although we may have experienced an in-
creased incidence limited to our geographic area, we
speculate that other health facilities that do not system-
atically apply laboratory confirmation to all infants with
respiratory symptoms may miss cases as well.
We did not observe deaths in our case series. Since
cases included in our study were admitted in a general
pediatrics ward we cannot exclude that other severe
cases were admitted to pediatric intensive care unit
(PICU). Crowcroft et al. [24] in a previously study, de-
scribed that about 20 % of infants <5 months admitted
to London PICU, with respiratory failure, apnea, or
acute life threatening episode had pertussis. They re-
ported two cases of death.
One of the barriers to wide use of RT-PCR for pertus-
sis may be costs associated with laboratory tests. Beyond
the tremendous impact of early therapy in pertussis
cases, it should be underlined that RT-PCR for pertussis
has an additional cost of nearly 30 euros or 38 USD per
test.
The use of molecular assays has become standard of
care in many setting recently. Mainly PCR has the ad-
vantage of offering result within several hours and in
most of the cases, it is considerated highly sensitive es-
pecially during the “late stage” of the disease. Moreover,
because is not affected by the use of drugs, one of the
major usefulness respect to cultures methods is that
specimens could be collected after antibiotic treatment
has been started. Phenotypic cultures, although highly
specific, fall in sensitivity with a reported range between
30 and 60 % of BP detection and increased time for re-
leasing test result compared with PCR [27]. We account
as great limitation of PCR that it’s unable to differentiate
asymptomatic carriers. In our series, all the patients
were admitted for acute respiratory symptoms and were
unvaccinated so we considered them as affected by per-
tussis and to be properly treated.
The PCR target used for diagnosis in this study was
IS481, consequently we cannot distinguish between BP,
Bordetella holmesii and Bordetella bronchiseptica.
Therefore, we consider it is unlikely that our data are a
possible overestimation of true data.
The IS481 sequence is represented from 50 up to 238
copies per cel in BP considering this an advantage in
term of high sensitive detection. Notwithstanding,
microbiologist, infectious disease practitioners and
pediatrics should be acquainted with the low presence of
this target in Bordetella holmesii (8 to 10 copies per gen-
ome) and Bordetella bronchiseptica as well [28–30].
Some laboratories perform a second PCR assay on
IS481-positive specimens using either a BP- or a Borde-
tella holmesii-specific target or both. However, these
other targets are at least ten fold less sensitive than
IS481 target since they are present in fewer copies of the
genome. A number of potential target sequences have
been proposed to increase the diagnosis of BP and Bor-
detella holmesii but there is no recommendation on
what is the best PCR diagnosis strategy to use at the
present time [16].
We recommend referring the final species differenti-
ation of pertussis illness depending on several factors as
by the setting of patients (more often related to im-
munocompromised individuals), or being contingent on
epidemiology contest [31].
Regarding Bordetella parapertusiss, in many clinical la-
boratories due to the high prevalence of pertussis in
order to better exploit the species responsible of pertus-
sis disease, it is suggested to investigate at the same time
RT-PCR assays by using IS481 for BP and IS 1001 spe-
cific of Bordetella parapertussis. These double check
methods could represent an appropriate procedure in
order to estimate the prevalence of Bordetella pertussis/
parapertussis infections, and to determinate their epide-
miologic characteristics in infants [32].
Although the duration of symptoms in BP+ patients
was longer than in the other diagnoses, 40 patients
(75.5 %) of 53 BP+ showed cough for less than 14 days.
According to the clinical case definition of CDC, WHO
[33] and ECDC [26], none of those patients should have
been reported. Similar observations were reported also
by others [25, 34]. The case definitions and classifica-
tions played an important role in improving the sensitiv-
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Fig. 1 Pertussis cases by month
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if these criteria are used purely clinically to select per-
tussis cases for confirmation in this age group, this may
result in considerable under-diagnosis of pertussis. The
clinical suspicion does not always meet all the clinical
criteria. Therefore, the current clinical criteria of pertus-
sis are all based on paroxysmal cough, but as van den
Brink et al have previously demonstrated, it is not a
good predictor in atypical pertussis infections [34]. The
development of an age-related case definition, as sug-
gested by the GPI [33], may be important to better as-
sess the real burden of pertussis in infants.
Our data support what has been previously reported
by Gonfiantini et al. [10] about the pertussis seasonality.
Many patients were affected by pertussis during summer
period; nevertheless some cases were reported even in
winter when most of respiratory viruses circulate among
population.
BP and RV co-infection was documented in 34 % of
our subjects. Conflicting results have been reported re-
garding the frequency of these concomitant [34–37].
The short duration of surveillance, the inclusion of
highly selected patient groups based on age and diagno-
sis may have contributed to these heterogeneous find-
ings. Therefore, in most of the previous studies, has
been taken into account only the co-infection between
RSV and BP. In our study we analyzed co-infections be-
tween BP and the most frequent RV.
From the clinical point of view, it’s important to
recognize co-infections, both for infection control and
clinical management. A diagnosis of respiratory virus in-
fection does not exclude pertussis and viceversa.
This study has some limitations. The retrospective
data collection from medical records can contain inac-
curacies regarding clinical information, but objective pa-
rameters were analyzed in order to reduce the possibility
of bias. Second, we cannot say if our results may be
generalizable to other pediatric settings in our country.
Nonetheless the use of laboratory test for pertussis con-
firmation is not widespread in Italy and, despite EU rec-
ommendations for case definition, most reported cases
are still diagnosed on a clinical base only. Lastly nine-
teen of our patients were treated with macrolides before
admission; this may have mitigated the clinical manifes-
tations in some cases.
Several strategies have been proposed for prevention
of pertussis in infants [38]. These include immunization
of adolescents and adults with tetanus, diphtheria toxoid
and acellular pertussis (Tdap) to boost waning immunity
against pertussis. Recent study, however, demonstrated
that after Tdap introduction in adolescents, the inci-
dence in this age group was reduced but the average in-
cidence of pertussis among infants younger than 1 year
did not significantly change. This is probably because of
increased vaccination coverage of those patients at the
highest risk to transmit disease is needed before the in-
direct effects of Tdap are fully realized [39, 40].
Another proposed strategy is maternal immunization
during the third trimester of pregnancy; from October
2011, the Advisory Committee on Immunization Prac-
tices (ACIP) recommended that unvaccinated pregnant
women receive a dose of Tdap [41]. Vaccination of
women with Tdap during pregnancy is expected to pro-
vide protection to infants from pertussis until they are
old enough to be vaccinated themselves [42]. Tdap given
to pregnant women stimulate the development of mater-
nal antipertussis antibodies, which pass through the pla-
centa, likely providing the newborn with protection
against pertussis in early life, and protect the mother
from pertussis around the time of delivery, making her
less likely to become infected and transmit pertussis to
her infant. In England an immunization program against
pertussis for pregnant women was introduced in Octo-
ber 2012 in response to a marked increase in pertussis
cases, particularly in young infants. The program achieved
60 % vaccine coverage and 90 % vaccine effectiveness in
preventing infant disease was demonstrated [43].
Vaccination of pregnant women is considered likely to
be the most cost-effective complementary strategy to
prevent pertussis-associated infant mortality [44].
Moreover, postpartum maternal immunization with
Tdap, as well as immunization of close household mem-
bers to prevent transmission of infection to vulnerable
infants (cocooning strategy) is currently recommended
by the Advisory Committee for Immunization Practices
to the Center of Disease Control and Prevention [45].
Since the impact of these strategies cannot be accurately
monitored without reliable surveillance data, we believe
that considering Bordetella pertussis infections in infants
≤3 months of age hospitalized with respiratory symp-
toms is essential.
Conclusions
In conclusions, clinical manifestations of pertussis in in-
fants can overlap with several different diseases. Some-
times presentation may mimic a viral respiratory tract
infection. Our data support a routinely use of RT-PCR
for pertussis in all infants ≤3 months of age with any re-
spiratory symptoms in order to implement appropriate
control measures in hospital and in the community at
large as the clinical suspicion is often not enough to well
recognize pertussis infection.
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